








Stephen J. Farr Ph.D. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Stephen J. Farr Ph.D.
Dir., Chief Executive Officer and President at Zogenix, Inc.


View Full Profile
Are you Stephen J. Farr Ph.D.? Claim your profile


 


Sign up for Equilar Atlas and view Stephen J. Farr Ph.D.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Stephen J. Farr Ph.D.'s  network and community.
												FOLLOW changes in Stephen J. Farr Ph.D.'s employment and money-in-motion.
												CONNECT with Stephen J. Farr Ph.D. through your network of contacts.
												








Stephen J. Farr Ph.D.'s Executive Work History


Current


Dir., Chief Executive Officer and President, 
Zogenix, Inc.


Board Member, 
Steadymed Ltd.


Past
To view Stephen J. Farr Ph.D.'s complete executive work history, sign up now
Education


														 B.S., 
															De Montfort University


														 Ph.D., 
															University of Wales


Age
58

 
 


Stephen J. Farr Ph.D.'s Biography



Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since our inception in May 2006. Dr. Farr has served as our Chief Executive Officer since April 2015 and served as our Chief Operating Officer from our inception to March 2013. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer with responsibility for research and development as well as business development. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Phar ...
(Read More)

			Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since our inception in May 2006. Dr. Farr has served as our Chief Executive Officer since April 2015 and served as our Chief Operating Officer from our inception to March 2013. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer with responsibility for research and development as well as business development. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the area of biopharmaceutics. Dr. Farr currently serves on the board of directors of SteadyMed Therapeutics, Inc., a publicly-traded company, as well as Oscillari, LLC and Flow Pharma, Inc. Dr. Farr is an adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales. As one of our co-founders and having served as our President since May 2006, Dr. Farr's extensive knowledge of our business, history and culture, as well as his significant experience in research and development and thorough knowledge of the pharmaceutical product development process, contributed to our board of directors' conclusion that he should serve as a director of our company.
		
Source: Zogenix, Inc. on 04/12/2017
		
	

 






Sign up for Equilar Atlas and view Stephen J. Farr Ph.D.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Stephen J. Farr Ph.D.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Stephen J. Farr Ph.D.'s  network and community.
												FOLLOW changes in Stephen J. Farr Ph.D.'s employment and money-in-motion.
												CONNECT with Stephen J. Farr Ph.D. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Stephen J. Farr Ph.D.


















Stephen J. Farr Ph.D.'s Connections (38)





Sign up now to view Stephen J. Farr Ph.D.'s 38 connections »









James C. Blair
Former Board Member, Clovis Oncology, Inc.









Louis C. Bock
Board Member, Orexigen Therapeutics, Inc.









V. Bryan Lawlis
Board Member, BioMarin Pharmaceutical Inc.









Erle T. Mast
Former Board Member, Zogenix, Inc.









Stan M. Benson
Former Senior Vice President, Sales and Marketing, Amgen Inc.









Bradley S. Galer
Former Executive Vice President and Chief Medical Officer, Zogenix, Inc.









Renee P. Tannenbaum
Former Board Member, Zogenix, Inc.









John M. Nehra
Board Member, DaVita HealthCare Partners









Igor Gonda
Former President and Chief Executive Officer, Aradigm Corporation









Roger L. Hawley
Board Member, Zogenix, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Elon R. Musk
CEO and Chairman, Tesla









David J. O'Connor
President and CEO, The Madison Square Garden Company









Claiborne P. Deming
Chairman of the Board, Murphy Oil Corporation












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
















ZGNX Stephen J. Farr Insider Trades for Zogenix Inc.


































Bulletin






Investor Alert







Tokyo Markets Open in:



US Market Snapshot
Currencies
Commodities


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Zogenix Inc.

                  NASDAQ: ZGNX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Zogenix Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 4:33 p.m.


ZGNX

/quotes/zigman/54271815/composite


$
13.40




Change

-0.0027
-0.02%

Volume
Volume 17,956
Quotes are delayed by 20 min








/quotes/zigman/54271815/composite
Previous close

$
			13.60
		


$
				13.40
			
Change

-0.20
-1.47%





Day low
Day high
$13.20
$13.80










52 week low
52 week high

            $7.50
        

            $15.40
        


















Insider Activity


Individual




Stephen J. Farr



Dr. Stephen J. Farr is a Member at Royal Pharmaceutical Society of Great Britain. He  is on the Board of Directors at SteadyMed Therapeutics, Inc., SteadyMed Ltd., Zogenix, Inc. and ICVRx LLC. Dr. Farr was previously employed as Chief Scientific Officer & Senior Vice President by Aradigm Corp., a Professor by University of Cardiff, and Scientific Director by Novo Nordisk A/S. He received his doctorate degree from The University of Wales.



Transactions


Date
Shares
Transaction
Value





06/03/2014
21


 
Disposition at $2 per share.


42


06/03/2014
1,591


 
Disposition at $2.03 per share.


3,230


06/02/2014
19,288


 
Disposition at $2.1 per share.


40,505


06/18/2013
50,000


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Stephen J. Farr 
President, Chief Executive Officer & Director




Mr. Michael P. Smith 
CFO, Secretary, Treasurer & Executive VP




Dr. Bradley S. Galer 
Chief Medical Officer & Executive Vice President




Dr. Thierry  Darcis 
Executive VP & General Manager-Europe Region




Dr. Gail M. Farfel 
Chief Development Officer & Executive VP




Mr. Steven A. Johnson 
Vice President & Compliance Officer




Ms. Catherine  O'Connor 
Senior Director-Commercial Communications




Dr. Arnold R. Gammaitoni 
Vice President-Medical & Scientific Affairs




Mr. Jeff D. Durflinger 
VP-Technical Operations & Product Supply




Dr. James B. Breitmeyer 
Director




Mr. Roger L. Hawley 
Director




Mr. Stephen H. Jenner 
Vice President-Marketing




Dr. Edward F. Smith 
Vice President-Regulatory Affairs & Drug Safety




Mr. Cam L. Garner 
Chairman




Dr. Renee P. Tannenbaum 
Independent Director




Mr. Louis C. Bock 
Independent Director




Mr. Mark C. Wiggins 
Independent Director




Mr. Erle T. Mast 
Independent Director
















Log In




1:54 PM EDT
July 23, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
1:48pTrafficking suspected after 8 people found dead, 30 injured in Walmart parking lot
12:28pThis is what might be next for O.J. Simpson after parole
12:09pWeekend roundup: Companies that may cut dividends | FAANG stocks and market bubbles | Enjoy London on the cheap
12:09pWhy you might want to avoid these 30 dividend stocks
12:09pAttention, shoppers: ‘Amazon effect’ is creating bargain stocks
12:05pAs GDP will show, U.S. economy on same track
12:00pStocks brace for volatility in earnings deluge; Fed meeting looms
11:52a'Dunkirk' storms U.S. box office with $50.5 million debut
11:27aO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
11:20aActor John Heard, ‘Home Alone’ dad, dead at 71
11:07aMicrosoft rides huge tax benefit from failing at smartphones to big earnings beat 
11:06aAmazon’s foray into groceries means more mergers of food companies, experts say
11:03aYogaWorks IPO pulled on valuation concerns, not market conditions
11:03aQualcomm’s issues go beyond Apple fight
11:02aPay TV expected to lose more than a million subscribers in latest quarter 
11:02aExxon earnings: Will stock trade higher on expected second-quarter beat?
11:01aAlphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
11:01aChipotle earnings: Media coverage of the latest illness scare will put earnings targets at risk
11:01aNolan’s cinematic vision in ‘Dunkirk’ is Hollywood’s best defense against Netflix
11:00aGE earnings: Departing CEO Immelt’s last chance to bring good things to investors
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






















































 












Stephen J. Farr, Zogenix, Inc. President & CEO - REDBOOKS








































Brands, Marketers, Agencies. Search Less. Sell More.





/   SIGN IN

GET A FREE TRIAL   
CONTACT US: (800) 908-5395





















Stephen J. Farr
President & CEO, Zogenix, Inc.

EMAIL: 
                      







              Real-time sales trigger feed - generated by REDBOOKS machine learning and natural language processing technology, tracking 800,000+ news sources to aggregate all new executives, job/role changes and news on decision makers, brands and agencies in the media/marketing industry.
              

              This sales feed is for Stephen J. Farr at Zogenix, Inc.. Stephen J. Farr works as President & CEO , acting in a Executive Management role .  Zogenix, Inc. is a leader in Pharmaceuticals & Health Care Products .
              REDBOOKS tracks personnel changes for advertisers spending over $1 million annually.
              

              For more Executive Management leads or media/marketing prospecting automation, start a free trial now.
              

Recent Related News


07/03/2017:


WIPO PUBLISHES PATENT OF STEPHEN J. FARR, BROOKS M. BOYD AND ZOGENIX INTERNATIONAL FOR "METABOLISM RESISTANT FENFLURAMINE...

GENEVA, July 3 -- Publication No. WO/2017/112701 was published on June 29.
Title of the invention: "METABOLISM RESISTANT FENFLURAMINE ANALOGS AND METHODS OF USING THE SAME."
Applicants: ZOGENIX INTERNATIONAL LIMITED (GB), Stephen J. Farr (US) and Brooks M. Boyd (US).
Inventors: Stephen J. Farr (US) and Brooks M. Boyd (US).
According to the abstract* posted by the World Intellectual Property Organization: "Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. .....

People In This Article:
Stephen J. Farr
 

06/23/2017:


Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome

Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced the U.S. Food & Drug Administration (FDA) has granted its investigational drug, ZX008 (low-dose fenfluramine), orphan drug designation for the treatment of Lennox Gastaut Syndrome (LGS), a refractory, debilitating childhood-onset epilepsy. The Orphan Drug Designation by the FDA follows the European Unions granting of Orphan Drug Designation for ZX008 in the treatment of LGS earlier this year.
.....

People In This Article:
Stephen J. Farr
 






Learn more about Stephen J. Farr  and 260,000+ key contacts

  Create targeted lead lists

  Gain insider knowledge with advanced machine  learning
  Real-time verified contact info



Enter Work Email:

Please enter email address.
 Please enter valid email address.









             Learn more about Stephen J. Farr and 260,000+ key contacts
            



























First Name *

 Please enter first name.




Last Name *

 Please enter last name.






Company Name *

 Please enter company name.






Email *





Phone *

 Please enter phone number.
 Please enter 10 digits number.





What industry are you in? *  
                (Please select one the categories below)
Please enter value for the industry.




                     Media Sales
                  




                     Production
                  




                     Ad-Tech/Mar-Tech
                  




                     Sponsorship Sales
                  



  Agency New Business
                  



  Other:
                  




What is your role? *
                 
                 (Please select one the categories below)
Please enter value for the role.



  C-Suite
                  



  VP/Manager
                  



  Sales Rep
                  



  Other:
                  














Thank you for registering for a Free REDBOOKS.com Trial!
We are processing your request and will be in touch shortly to get you started!
For Immediate Assistance, please call us at (800) 908-5395 or email us at info@redbooks.com


























Home
Learn More
FREE Trial


Features




AD THINK Events
Thought Leadership Events
Top Advertiser Directory
Top Agency Directory



Add Your Agency
Update Your Agency
Agency Showcase
Advertising Associations
Creative Spotlight
Services and Suppliers


About Us
Blog
Contact Us
Jobs
Terms & Conditions
Privacy Policy





Customer Support
(800) 908-5395
Connect with us




















Copyright © 2017 Red Books LLC. All rights reserved
































Stephen J Farr - Wooster, OH | Intelius



























Sign In



We found Stephen J Farr in Wooster, OH


Stephen J Farr

                                                                           Intelius found that Stephen J Farr  is  a male between 60 and 70 years old from Wooster, OH.  We have connected them to
                10 addresses,
                3 phones,
                and 8 relatives or associates.
         






Get Report Now

Age

Stephen J Farr is in his 60s

Stephen Has Lived In

Wooster, OH
Lincoln, NE
Vancouver, WA

Stephen's Relatives

Ardith Farr
Jack Farr
Janelle Amarillas
Lori Whitted







Stephen J Farr



Zodiac SignVirgo



GenderMale



Get Report Now










Want to know more about Stephen? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Stephen, or use our people search engine to find others.
Get Background Check on Stephen J Farr
Get a Criminal Check on Stephen J Farr
Get a Public Record Report on Stephen J Farr
Get a People Search Report on Stephen J Farr


Stephen J Farr's Contact Information
Known Cities Lived In
Find out where Stephen J Farr has lived as well as Stephen J Farr's phone numbers and email addresses.




Stephen J Farr Has Lived in 4 States
Ohio Address for Stephen J Farr


3072 N G***** C***** R* 

Wooster, OH


Has Lived In

Wooster, OH
Lincoln, NE


Get Full Address Report










Phone Numbers Associated with Stephen J Farr

(330) ***-**** - Wooster, OH 
(360) ***-**** - Vancouver, WA 
(360) ***-**** - Vancouver, WA 


Get Full Phone Report



Email Addresses Associated with Stephen J Farr

l******h@***.com
s*************s@***.com


Get Email Report




Stephen J Farr's Education Information
Known Schools Attended
Learn about Stephen J Farr's academic history.  Find out which schools Stephen J Farr attended, the dates attended as well as the degrees Stephen J Farr received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Stephen J Farr Has Attended 2 Schools
Portland Adventist Academy 1971 – 1973                              
Laurelwood Academy               1969 – 1973                              


Stephen J Farr's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Stephen J Farr


Stephen J Farr's known Social Networks And Potential Email Matches

Find all of Stephen J Farr's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Stephen Farr
Username Matches

                  StephenFarr
                  FarrStephen
                  Stephen.Farr
                  Farr.Stephen
                  Stephen_Farr
                  Farr_Stephen
                  Stephen-Farr
                  Farr-Stephen
                  SFarr
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
S Farr







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.















Stephen J. Farr - Patent Inventor























Stephen J. Farr patentsRecent patents with Stephen J. Farr listed as an inventor - additional entries may be under other spellings.


















Stephen J. Farr - Related organizations: Zogenix International Limited patents, Zogenix, Inc. patents, Oscillari Llc patents, Aradigm Corporation patents









Metabolism resistant fenfluramine analogs and methods of using the same
		      06/22/17 - 20170174614 - Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need
					Inventors: Stephen J. Farr, Brooks M. Boyd













Methods of treating lennox-gastaut syndrome using fenfluramine
		      03/02/17 - 20170056344 - A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a
					Inventors: Stephen J. Farr, Bradley S. Galer













Needle free injectors
		      07/14/16 - 20160199579 - Improved needle free injectors comprising of a energy sources, triggering mechanisms, impact members, and drug delivery pistons are disclosed. In one preferred embodiment, the triggering mechanism comprises a spool which seals an energy source comprised of compressed gas and a component for releasing the spool to release the pressurized gas
					Inventors: Brooks Boyd, Stephen J. Farr, Jeffery A. Schuster, Andy Fry, Andy Pocock, Brennan Miles, Chris Hurlstone, Joe Daintrey













Acoustic based drug delivery monitor
		      06/16/16 - 20160166766 - A drug delivery monitoring system comprising a monitor is disclosed that utilizes sound to monitor the occurrence and properties of a drug delivery event. The monitor is affixed to the exterior of a drug delivery device or drug container, and thus does not require disassembly of the drug delivery device
					Inventors: Jeffrey A. Schuster, Stephen J. Farr 
		    












Novel formulations for treatment of migraine
		      06/02/16 - 20160151571 - Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and
					Inventors: Stephen J. Farr, John Turanin, Roger Hawley, Jeffrey A. Schuster













Vibration sensor based drug delivery monitor
		      05/12/16 - 20160129182 - A monitoring system comprising a monitor is disclosed that utilizes a vibration sensor to monitor the occurrence and properties of an event. The monitor does not require disassembly of the device to be monitored, or interfere with the operation of the device to be monitored, because the monitor is affixed
					Inventors: Jeffrey A. Schuster, Stephen J. Farr, Reuben Hale













Novel formulations for treatment of migraine
		      02/25/16 - 20160051466 - Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and
					Inventors: Stephen J. Farr, John Turanin, Roger Hawley, Jeffrey A. Schuster













Novel formulations for treatment of migrane
		      05/29/14 - 20140148485 - Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and
					Inventors: Stephen J. Farr, John Turanin, Roger Hawley, Jeffrey A. Schuster













Novel formulations for treatment of migraine
		      09/05/13 - 20130231311 - Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and
					Inventors: Stephen J. Farr, John Turanin, Roger Hawley, Jeffrey A. Schuster













Viscous formulations and their use in needle-free injection
		      11/22/12 - 20120296270 - Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which
					Inventors: Brooks M. Boyd, Sujata Mudumba, Stephen J. Farr 
		    












Viscous formulations and their use in needle-free injection
		      08/11/11 - 20110196336 - Formulations are described that are viscous and will benefit from needle-free delivery at high driving pressures. Conventional delivery of these viscous formulations by hypodermic syringes is inconvenient as well as painful. Formulations include those which have a viscosity of about 5 cS or more at about 20° C. and which
					Inventors: Brooks M. Boyd, Sujata Mudumba, Stephen J. Farr 
		    












Novel formulations for treatment of migraine
		      05/19/11 - 20110118189 - Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and
					Inventors: Stephen J. Farr, John Turanin, Roger Hawley, Jeffrey A. Schuster













Method of treating diabetes mellitus in a patient
		      10/01/09 - 20090241950 - The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially
					Inventors: Igor Gonda, Reid M. Rubasamen, Stephen J. Farr 
		    



### Stephen J. Farr patent invention listingsThe bibliographic references displayed about Stephen J. Farr's patents are for a recent sample of Stephen J. Farr's publicly published patent applications. The inventor/author may have additional bibliographic citations listed at the USPTO.gov. FreshPatents.com is not associated or affiliated in any way with the author/inventor or the United States Patent/Trademark Office but is providing this non-comprehensive sample listing for educational and research purposes using public bibliographic data published and disseminated from the United States Patent/Trademark Office public datafeed. This information is also available for free on the USPTO.gov website.  If Stephen J. Farr filed recent patent applications under another name, spelling or location then those applications could be listed on an alternate page. If no bibliographic references are listed here, it is possible there are no recent filings or there is a technical issue with the listing--in that case, we recommend doing a search on the USPTO.gov website. ###Sign up for the FreshPatents.com FREE Keyword Monitor and check for keyword phrases (ie. "RFID" , "wireless", "web development", "fuel cells" etc.)...You will be notified when new patent applications and inventions are published that match your keywords. Also you can save for later research public patent/invention documents using our FREE Organizer. It takes only 30 seconds to sign up or login.Advertise on FreshPatents.com - Rates & Info###Design/code © 2014 FreshContext LLC/Freshpatents.com.Patent data source: patents published by the United States Patent and Trademark Office (USPTO)Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and may contain additional data/images. FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents and there may be applicable trademarks or servicemarks within the documents.FreshPatents.com Support - Terms & Conditions









Stephen J. Farr











































Home
Search
Sign-In/Up
Contracts
Dictionary
Clauses
Companies
People

About
FAQ
Blog








Follow Stephen J. Farr contracts
Click to sign-up for email updates.

      Loading...
    





Home



Sample Contracts



By Executive


Stephen J. Farr


Stephen J. Farr

SEC Documents
Filings
Personal financials
Insider transactions
Previous Companies

Zogenix
(NASDAQ:ZGNX)
Aradigm Corp



Sample Contracts with Stephen J. Farr




General Release of Claims
(May 4th, 2017)
THIS GENERAL RELEASE OF CLAIMS (this "Release") is entered into by and between Zogenix, Inc., a Delaware corporation (the "Company"), and Ann Rhoads ("Executive"), as of the Effective Date (as defined below).




Employment Agreement
(May 4th, 2017)
THIS EMPLOYMENT AGREEMENT (this "Agreement") is entered into by and between Zogenix, Inc., a Delaware corporation (the "Company"), and Michael Smith ("Executive"), and shall be effective as of January 16, 2017 (the "Effective Date").




Amendment #4 to the Manufacturing Services Agreement
(March 10th, 2017)
This Amendment #4 (the "Amendment #4") to the Manufacturing Services Agreement dated February 28, 2013 with an effective date of November 1, 2013 is entered into by and between Patheon UK Limited, a corporation existing under the laws of England and Wales, with offices at Kingfisher Drive, Covingham, Swindon, Wiltshire, SN3 SBZ, England ("Patheon") and Zogenix, Inc., a corporation existing under the laws of Delaware, with offices at 12400 High Bluff Drive, Suite 650, San Diego, California, 92130, USA ("Zogenix").




Third Amendment to Office Lease Between Emery Station Joint Venture, Llc
(Landlord) and Zogenix, Inc. (Tenant)
(August 10th, 2015)
THIS THIRD AMENDMENT TO OFFICE LEASE ("Third Amendment") is entered into as of July 16, 2015 (the "Third Amendment Effective Date"), by and between Emery Station Joint Venture, LLC, a California limited liability company ("Landlord") and Zogenix, Inc., a Delaware corporation ("Tenant"), with reference to the following facts:




Employment Agreement
(August 10th, 2015)
THIS EMPLOYMENT AGREEMENT (this "Agreement") is entered into by and between Zogenix, Inc., a Delaware corporation (the "Company"), and Gail M. Farfel, Ph.D. ("Executive"), and shall be effective as of June 29, 2015 (the "Effective Date").




Employment Agreement
(August 10th, 2015)
THIS EMPLOYMENT AGREEMENT (this "Agreement") is entered into by and between Brabant Pharma, Ltd. (the "Company"), and Thierry Darcis ("Executive"), and shall be effective as of June 29, 2015 (the "Effective Date").




Amended and Restated Employment Agreement
(August 10th, 2015)
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this "Agreement") is entered into by and between Zogenix, Inc., a Delaware corporation (the "Company"), and Stephen J. Farr, Ph.D. ("Executive"), and shall be effective as of April 27, 2015 (the "Effective Date").




General Release of Claims
(May 11th, 2015)
THIS GENERAL RELEASE OF CLAIMS (this "Release") is entered into by and between Zogenix, Inc., a Delaware corporation (the "Company"), and Roger Hawley ("Executive"), as of the Effective Date (as defined below).




Amendment No. 3 - Development and Option Agreement
(March 11th, 2015)
THIS AMENDMENT NO. 3 - DEVELOPMENT AND OPTION AGREEMENT (the "Amendment No. 3") is made as of October 30, 2014 (the "Amendment No. 3 Effective Date"), by and between ALTUS FORMULATION INC., a Quebec company, having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada ("Altus"), and ZOGENIX, INC., a Delaware corporation, having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA  92130 USA ("Zogenix").  Each of Altus and Zogenix are sometimes referred to herein individually as a "Party" and together as the "Parties".




Teva | North America November 5, 2014 Zogenix, Inc. 12400 High Bluff Drive
Suite 650 San Diego, CA 92130 Attn: Stephen J. Farr, President Re: Right of
Reference Dear Mr. Farr:
(March 11th, 2015)
This binding letter agreement (this "Letter Agreement"), effective as of the date first set forth above ("Effective Date"), confirms the understanding and agreement between Teva Pharmaceuticals USA, Inc. ("Teva") and Zogenix, Inc. ("Zogenix") with regard to the grant by Zogenix to Teva of a right of reference to the carcinogenicity data identified below that were generated by Zogenix for the Zogenix Product (as defined below).




Loan and Security Agreement
(December 31st, 2014)
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this Agreement) dated as of December 30, 2014 (the Effective Date) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (Oxford), as collateral agent (together with its successors and assigns in such capacity, Collateral Agent), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (Bank or SVB) (each a Lender and collectively, the Lenders), and ZOGENIX, INC., a Delaware corporation with offices located at 12400 High Bluff Drive, Suite 650, San Diego, California 92130 (Borrower), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties a




Amendment No. 2 - Development and Option Agreement
(November 6th, 2014)
THIS AMENDMENT NO. 2 - DEVELOPMENT AND OPTION AGREEMENT (the "Amendment No. 2") is made as of September 15th, 2014 (the "Amendment No. 2 Effective Date"), by and between ALTUS FORMULATION INC., a Quebec company, having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada ("Altus"), and ZOGENIX, INC., a Delaware corporation, having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA  92130 USA ("Zogenix").  Each of Altus and Zogenix are sometimes referred to herein individually as a "Party" and together as the "Parties".




License Agreement
(August 6th, 2014)
This License Agreement (this "Agreement"), effective as of the Closing ("Effective Date"), is entered into by and between Zogenix, Inc., a Delaware corporation ("Zogenix"), and Endo Ventures Bermuda Limited, a Bermuda company ("Endo").




Certain Material (Indicated by an Asterisk) Has Been Omitted From This Document
Pursuant to a Request for Confidential Treatment. The Omitted Material Has Been
Filed Separately With the Securities and Exchange Commission. Manufacturing and
Supply Agreement
(August 6th, 2014)
This Manufacturing and Supply Agreement (together with all exhibits attached hereto, the "Agreement"), effective as of May 16, 2014 (the "Effective Date"), is by and between Zogenix, Inc., a Delaware corporation, with its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA 92130 ("Zogenix") and Endo Ventures Limited, a company organized under the Laws of Ireland, with its principal place of business at No. 33 Fitzwilliam Square, Dublin 2, Ireland ("Endo").




Amendment No. 1 - Development and Option Agreement
(May 8th, 2014)
THIS AMENDMENT NO. 1 - DEVELOPMENT AND OPTION AGREEMENT (the "Amendment No. 1") is made as of March 10th, 2014 (the "Amendment No. 1 Effective Date"), by and between ALTUS FORMULATION INC., a Quebec company, having its principal place of business at 17800 Rue Lapointe, Mirabel Quebec J7J 1P3, Canada ("Altus"), and ZOGENIX, INC., a Delaware corporation, having its principal place of business at 12400 High Bluff Drive, Suite 650, San Diego, CA  92130 USA ("Zogenix").  Each of Altus and Zogenix are sometimes referred to herein individually as a "Party" and together as the "Parties".




First Amendment to Battelle/Zogenix Co-Marketing and Option Agreement
(May 9th, 2013)
This First Amendment ("Amendment") to the Co-Marketing and Option Agreement dated March 29, 2012  ("Agreement") is made and entered into as of the  21st day of March, 2013 and is by and between Battelle Memorial Institute ("Battelle") and Zogenix, Inc. ("Zogenix") (Battelle and Zogenix are individually referred to as a "Party" and collectively referred to as the "Parties").




Development and License Agreement Between Durect Corporation and Zogenix, Inc.
Dated as of July 11, 2011
(August 12th, 2011)
THIS DEVELOPMENT AND LICENSE AGREEMENT (this Agreement), effective July 11, 2011 (Effective Date), is entered into by and between Durect Corporation, a corporation organized and existing under the laws of the State of Delaware, U.S.A. with a place of business at 2 Results Way, Cupertino, CA 95014 (Durect), and Zogenix, Inc., a corporation organized and existing under the laws of Delaware, with a place of business at 12671 High Bluff Drive, Suite 200, San Diego, CA 92130 (Zogenix).





Follow Stephen J. Farr contracts
Click to sign-up for email updates.

      Loading...
    












×









      Have an account? Sign in here.

Law Insider
Recover your password







No account? Register Now!


No account? Register Now!
Sign in
by using one of this services











or







Forgot your password?


Have an account? Sign in here.
Join Law Insider
for Free
by using one of this services











or







By registering you agree to our
      terms of service.










Contract and Agreement Category List











































Home
Search
Sign-In/Up
Contracts
Dictionary
Clauses
Companies
People

About
FAQ
Blog







Sample Contract Categories 

a

b

c

d

e

f

g

h

i

j

k

l

m

n

o

p

q

r

s

t

u

v

w

x

y

z


abcdefghijklmnopqrstuvwxyz


337k
		Delaware
	

277k
		New York
	

113k
		California
	

70k
		Texas
	

68k
		Agreement
	

62k
		Nevada
	

46k
		Florida
	

44k
		Maryland
	

40k
		Illinois
	

38k
		Employment Agreement
	

38k
		Washington
	

37k
		Amended And Restated
	

36k
		Massachusetts
	

34k
		New Jersey
	

33k
		Pennsylvania
	

28k
		Georgia
	

28k
		Colorado
	

26k
		Ohio
	

25k
		Minnesota
	

25k
		Virginia
	

21k
		North Carolina
	

20k
		Incentive Plan
	

19k
		Credit Agreement
	

19k
		Amendment
	

16k
		Connecticut
	

16k
		Michigan
	

15k
		Indiana
	

14k
		Registration Rights Agreement
	

14k
		Recitals
	

13k
		Tennessee
	

13k
		Arizona
	

13k
		Missouri
	

12k
		Purchase Agreement
	

12k
		Promissory Note
	

12k
		Indenture
	

11k
		Warrant
	

11k
		Louisiana
	

11k
		Kansas
	

11k
		Utah
	

11k
		Wisconsin
	

10k
		Oklahoma
	

9k
		Securities Purchase Agreement
	

9k
		Agreement And Plan Of Merger
	

8k
		Iowa
	

8k
		Supplemental Indenture
	

8k
		Note
	

8k
		Equity Incentive Plan
	

7k
		Kentucky
	

7k
		Stock Purchase Agreement
	

7k
		Alabama
	














×









      Have an account? Sign in here.

Law Insider
Recover your password







No account? Register Now!


No account? Register Now!
Sign in
by using one of this services











or







Forgot your password?


Have an account? Sign in here.
Join Law Insider
for Free
by using one of this services











or







By registering you agree to our
      terms of service.










Stephen Farr, Zogenix Inc: Profile & Biography - Bloomberg


































































  























Feedback





Stephen Farr

President/CEO/Co-Founder,
Zogenix Inc






Career History




President/CEO/Co-Founder
Zogenix Inc, 4/2015-PRESENT


Adjunct Professor
Virginia Commonwealth University, PRESENT


President/Co-Founder
Zogenix Inc, 3/2013-4/2015


President/CEO/Co-Founder
Zogenix Inc, 8/2006-3/2013


President/COO
Zogenix Inc, 5/2006-8/2006


Senior VP/Chf Scientific Ofcr
Aradigm Corp, 4/2003-8/2006


Vice President
Aradigm Corp, 8/2000-4/2003


Director:Pharmaceuticals Div
Aradigm Corp, 1995-2000


Show More









Website:
www.zogenix.com






Corporate Information
Address:

5858 Horton Street
Suite 455
Emeryville, CA 94608
United States


Phone:
1-510-550-8300


Fax:
1-858-259-1166


Web url:
www.zogenix.com











From The Web












Personal Information



Education




PhD








Memberships



Board Memberships




Steadymed Ltd


Board Member, 5/2012-PRESENT




Zogenix Inc


Board Member, 5/2006-PRESENT






Other Memberships




American Assn of Pharmaceutical Scientists


Fellow









Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data











































 


   Stephen Farr | Zogenix , Inc. | ZoomInfo.com



Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #fed5b020-6fcf-11e7-b7d6-6d3dd2450d61
          





            Powered by
            PerimeterX
            , Inc.
          














Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #ff012cf0-6fcf-11e7-befb-43e56d07171c
          





            Powered by
            PerimeterX
            , Inc.
          














Access to this page has been denied.














Please verify you are a human





            Please click "I am not a robot" to continue
          



            Access to this page has been denied because we believe you are using automation tools to browse the website.
          

            This may happen as a result of the following:
          


              Javascript is disabled or blocked by an extension (ad blockers for example)
            

              Your browser does not support cookies
            


            Please make sure that Javascript and cookies are enabled on your browser and that you are not blocking them from loading.
          

            Reference ID: #ff2b7140-6fcf-11e7-baa8-2126f1252ade
          





            Powered by
            PerimeterX
            , Inc.
          










